The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Trius Therapeutics, Inc. (NASDAQ: TSRX) (“Trius” or “the Company”), concerning the Company’s proposed acquisition by Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) (“Cubist”). Under the terms of the merger agreement, Trius shareholders will receive $13.50 in cash for each share of Trius common stock they own. Trius shareholders will also be eligible to receive one Contingent Value Right of $1.00 per share if net sales of tedizolid in the U.S., Canada, and Europe are greater than or equal to $125 million in 2016 and up to an additional $1.00 per share, paid on a pro rata basis, for 2016 net sales between $125 and $135 million. The total transaction is valued at approximately $818 million. At least one analyst has set a target price of $20.00 for Trius shares.

The investigation is focused on the potential unfairness of the consideration to shareholders, the process by which Trius’ Board of Directors considered the transaction, and potential conflicts of interest among the Company’s Board members.

If you are interested in discussing your rights as a Trius shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (202)-337-8000 or by email at

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at Attorney advising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010